H-Index & Metrics Best Publications

H-Index & Metrics

Discipline name H-index Citations Publications World Ranking National Ranking
Immunology D-index 56 Citations 14,210 129 World Ranking 2095 National Ranking 172

Overview

What is he best known for?

The fields of study he is best known for:

  • Cancer
  • Internal medicine
  • Immune system

Francesco Dazzi focuses on Mesenchymal stem cell, Stem cell, Immunology, Cell biology and Internal medicine. He combines subjects such as Clinical uses of mesenchymal stem cells, Stromal cell, Cancer stem cell, Cell cycle and Bone marrow with his study of Mesenchymal stem cell. His Stem cell research integrates issues from Endothelial stem cell, Adult stem cell and T cell.

As part of his studies on Immunology, Francesco Dazzi frequently links adjacent subjects like Cytotoxic T cell. His biological study spans a wide range of topics, including IL-2 receptor and Antigen-presenting cell. His Internal medicine research is multidisciplinary, relying on both In vitro and Surgery.

His most cited work include:

  • Bone marrow mesenchymal stem cells inhibit the response of naive and memory antigen-specific T cells to their cognate peptide. (1397 citations)
  • Bone marrow mesenchymal stem cells induce division arrest anergy of activated T cells. (920 citations)
  • Mesenchymal stem cells inhibit dendritic cell differentiation and function by preventing entry into the cell cycle. (381 citations)

What are the main themes of his work throughout his whole career to date?

His scientific interests lie mostly in Immunology, Mesenchymal stem cell, Stem cell, Transplantation and Internal medicine. His Mesenchymal stem cell study is concerned with the larger field of Cell biology. His Cell biology research focuses on subjects like IL-2 receptor, which are linked to T lymphocyte.

The various areas that Francesco Dazzi examines in his Stem cell study include Pathology and Adult stem cell. His work deals with themes such as Cell therapy, Histocompatibility and Intensive care medicine, which intersect with Transplantation. His Internal medicine study combines topics in areas such as Gastroenterology, Surgery and Oncology.

He most often published in these fields:

  • Immunology (50.44%)
  • Mesenchymal stem cell (34.07%)
  • Stem cell (30.97%)

What were the highlights of his more recent work (between 2017-2021)?

  • Mesenchymal stem cell (34.07%)
  • Cancer research (15.49%)
  • Stromal cell (10.62%)

In recent papers he was focusing on the following fields of study:

Francesco Dazzi mostly deals with Mesenchymal stem cell, Cancer research, Stromal cell, Immune system and Transplantation. The study incorporates disciplines such as Cytotoxic T cell and Internal medicine, Clinical trial in addition to Mesenchymal stem cell. His studies deal with areas such as Cancer, Stem cell and Apoptosis as well as Cancer research.

His Stem cell research includes elements of Chronic myelogenous leukemia and Bone marrow. His Immune system study also includes

  • Cell that intertwine with fields like Cancer stem cell and Regeneration,
  • Inflammation, Haematopoiesis and Fludarabine most often made with reference to Myeloid. His Transplantation research incorporates themes from Cell therapy, Immunology and Intensive care medicine.

Between 2017 and 2021, his most popular works were:

  • Hematopoietic stem cell transplantation in its 60s: A platform for cellular therapies (58 citations)
  • Challenges for mesenchymal stromal cell therapies. (46 citations)
  • Bi-directional cell-pericellular matrix interactions direct stem cell fate (42 citations)

In his most recent research, the most cited papers focused on:

  • Cancer
  • Internal medicine
  • Immune system

Francesco Dazzi mainly focuses on Mesenchymal stem cell, Stromal cell, Clinical trial, Internal medicine and Cancer research. He has researched Stromal cell in several fields, including Myeloid, Stem cell, Cell biology and Immune system. Francesco Dazzi carries out multidisciplinary research, doing studies in Stem cell and Chemistry.

Francesco Dazzi interconnects Inflammation, Reprogramming, Tissue homeostasis and Cell type in the investigation of issues within Cell biology. His Clinical trial research is multidisciplinary, incorporating elements of Disease, Inflammatory bowel disease and Oncology. Bone marrow and Intestinal mucosa are among the areas of Internal medicine where he concentrates his study.

This overview was generated by a machine learning system which analysed the scientist’s body of work. If you have any feedback, you can contact us here.

Best Publications

Bone marrow mesenchymal stem cells inhibit the response of naive and memory antigen-specific T cells to their cognate peptide.

Mauro Krampera;Sarah Glennie;Julian Dyson;Diane Scott.
Blood (2003)

2043 Citations

Bone marrow mesenchymal stem cells induce division arrest anergy of activated T cells.

Sarah Glennie;Inês Soeiro;Peter J. Dyson;Eric W.-F. Lam.
Blood (2005)

1358 Citations

The risk of recurrent venous thromboembolism in patients with an Arg506→Gln mutation in the gene for factor V (factor V Leiden)

Paolo Simioni;Paolo Prandoni;Anthonie W.A. Lensing;Alberta Scudeller.
The New England Journal of Medicine (1997)

525 Citations

Mesenchymal stem cells inhibit dendritic cell differentiation and function by preventing entry into the cell cycle.

Rajesh Ramasamy;Henrietta Fazekasova;Eric W.-F. Lam;In s Soeiro.
Transplantation (2007)

518 Citations

Mesenchymal stem cells inhibit proliferation and apoptosis of tumor cells: impact on in vivo tumor growth.

R Ramasamy;E. W. F. Lam;I. Soeiro;Veronica Tisato.
Leukemia (2007)

473 Citations

The role of mesenchymal stem cells in haemopoiesis.

Francesco Dazzi;Rajesh Ramasamy;Sarah Glennie;Simon P. Jones.
Blood Reviews (2006)

457 Citations

Mesenchymal stem cells: the fibroblasts' new clothes?

Muzlifah A. Haniffa;Matthew P. Collin;Christopher D. Buckley;Francesco Dazzi.
Haematologica (2009)

414 Citations

European LeukemiaNet criteria for failure or suboptimal response reliably identify patients with CML in early chronic phase treated with imatinib whose eventual outcome is poor.

David Marin;Dragana Milojkovic;Eduardo Olavarria;Jamshid S. Khorashad.
Blood (2008)

393 Citations

Comparison of single-dose and escalating-dose regimens of donor lymphocyte infusion for relapse after allografting for chronic myeloid leukemia

Francesco Dazzi;R. M. Szydlo;C. Craddock;N. C. Cross.
Blood (2000)

387 Citations

Characterization and Clinical Application of Human CD34+ Stem/Progenitor Cell Populations Mobilized into the Blood by Granulocyte Colony-Stimulating Factor

Myrtle Y. Gordon;Nataša Levičar;Madhava Pai;Philippe Bachellier.
Stem Cells (2006)

384 Citations

If you think any of the details on this page are incorrect, let us know.

Contact us

Best Scientists Citing Francesco Dazzi

Jorge E. Cortes

Jorge E. Cortes

Augusta University

Publications: 65

John M. Goldman

John M. Goldman

Imperial College London

Publications: 64

Jane F. Apperley

Jane F. Apperley

Imperial College London

Publications: 64

Hagop M. Kantarjian

Hagop M. Kantarjian

The University of Texas MD Anderson Cancer Center

Publications: 61

Andreas Hochhaus

Andreas Hochhaus

Friedrich Schiller University Jena

Publications: 49

Olle Ringdén

Olle Ringdén

Karolinska Institute

Publications: 46

Xiao-Jun Huang

Xiao-Jun Huang

Peking University

Publications: 42

Franco Locatelli

Franco Locatelli

Bambino Gesù Children's Hospital

Publications: 41

Jerald P. Radich

Jerald P. Radich

Fred Hutchinson Cancer Research Center

Publications: 37

Jacques Galipeau

Jacques Galipeau

University of Wisconsin–Madison

Publications: 37

Giuseppe Saglio

Giuseppe Saglio

University of Turin

Publications: 35

Michael W. Deininger

Michael W. Deininger

Huntsman Cancer Institute

Publications: 34

Christian Jorgensen

Christian Jorgensen

University of Montpellier

Publications: 33

Mauro Krampera

Mauro Krampera

University of Verona

Publications: 33

Michele Baccarani

Michele Baccarani

University of Bologna

Publications: 32

Yufang Shi

Yufang Shi

Soochow University

Publications: 31

Something went wrong. Please try again later.